Ms Francesca Mordant
Research Assistant
Department of Microbiology and Immunology
48 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial
DOI: 10.1093/infdis/jiaf5682026
Journal article
Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2
DOI: 10.1128/mbio.03221-252025
Journal article
P-98. The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in BNT162b2 primed individuals aged 18-< 50 and 50-< 70 years old
DOI: 10.1093/ofid/ofae631.3052025
Journal article
86. The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-< 70 years old
DOI: 10.1093/ofid/ofae631.0232025
Journal article
Human guanylate-binding protein (GBP) 1 inhibits replication of severe acute respiratory syndrome coronavirus 2
DOI: 10.1128/jvi.00823-252024
Journal article
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old
DOI: 10.1016/j.jinf.2024.1063462024
Journal article
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old
DOI: 10.1016/j.jinf.2024.106286
RECENT SCHOLARLY WORKS
2024
Journal article
Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection
DOI: 10.1128/jvi.00531-242023
Journal article
Ancestral, Delta, and Omicron (BA.1) SARS-CoV-2 strains are dependent on serine proteases for entry throughout the human respiratory tract
DOI: 10.1016/j.medj.2023.08.0062023
Journal article
377. Phase I trial of two novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as 4th dose boosters
DOI: 10.1093/ofid/ofad500.447